http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-PI0813662-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_29800004a1adc1fb9b840e645d147be5 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6031 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00113 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385 |
| filingDate | 2008-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf8be185858b4cf323e2bb2b3c32b3fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f30b5dd3b6fcf5a584de7257c746af6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b487f641445998e29c0fbadc92eab92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26606b8e688794e6028d559099529b79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cbeb693ac53c97aca48d39d21d034c6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3aafd9a47c724ffcb6fd6ac540a1ee67 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1a74ee5b278321e1fe82d49daf7d4c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_103ba7fe1f54523fb584fa6a7d8b126f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d9a6f29030c9c4b2af2217bb41c9eec |
| publicationDate | 2019-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-PI0813662-B1 |
| titleOfInvention | VACINAL COMPOSITION, PROCESS FOR OBTAINING VACINAL COMPOSITION, AND USING VACINAL COMPOSITION |
| abstract | Vaccine composition, process for obtaining a vaccine composition, and use of a vaccine composition The present invention relates to the field of biotechnology and more specifically to human health. In particular, the present invention describes a vaccine composition for its therapeutic use in cancer patients. The vaccine composition described in the present invention is active in a chemical conjugate between recombinant human epidermal growth factor (hregf) and recombinant protein p64k. Further, specific conditions for carrying out a conjugation reaction are described which enable said controlled conjugate to be obtained in a controlled and reproducible manner. In another aspect, the present invention relates to a process for the purification of the chemical conjugate which not only brings greater purity to the therapeutic vaccine composition, but surprisingly increases immunological activity, causing significant increases in anti-egf antibody titers in humans. Additionally the present invention provides the methodology for achieving a vaccine preparation with more than one dose presentation type (total milligrams of egf-p64k / vial conjugates). This versatility in the presentation of the vaccine preparation allows to increase the immunization dose per patient, but this should increase the frequency of immunization and / or the number of immunization sites. Finally, the present invention embodies a sanitary process for obtaining the parenterally administered cancer therapy vaccine preparation. |
| priorityDate | 2007-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.